TITLE

Safety and efficacy of liposomal amphotericin B compared with conventional amphotericin B for induction therapy of histoplasmosis in patients with AIDS

AUTHOR(S)
Johnson, Philip C.; Wheat, L. Joseph; Cloud, Gretchen A.; Goldman, Mitchell; Lancaster, Dan; Bamberger, David M.; Powderly, William G.; Hafner, Richard; Kauffman, Carol A.; Dismukes, William E.; U.S. National Institute of Allergy and Infectious Diseases Mycoses Study Group
PUB. DATE
July 2002
SOURCE
Annals of Internal Medicine;7/16/2002, Vol. 137 Issue 2, p105
SOURCE TYPE
Academic Journal
DOC. TYPE
journal article
ABSTRACT
Background: In patients with moderate to severe histoplasmosis associated with AIDS, the preferred treatment has been the deoxycholate formulation of amphotericin B. However, serious side effects are associated with use of amphotericin B.Objective: To compare amphotericin B with liposomal amphotericin B for induction therapy of moderate to severe disseminated histoplasmosis in patients with AIDS.Design: Randomized, double-blind, multicenter clinical trial.Setting: 21 sites of the U.S. National Institute of Allergy and Infectious Diseases Mycoses Study Group.Patients: 81 patients with AIDS and moderate to severe disseminated histoplasmosis.Measurements: Clinical success, conversion of baseline blood cultures to negative, and acute toxicities that necessitated discontinuation of treatment.Results: Clinical success was achieved in 14 of 22 patients (64%) treated with amphotericin B compared with 45 of 51 patients (88%) receiving liposomal amphotericin B (difference, 24 percentage points [95% CI, 1 to 52 percentage points]). Culture conversion rates were similar. Three patients treated with amphotericin B and one treated with liposomal amphotericin B died during induction (P = 0.04). Infusion-related side effects were greater with amphotericin B (63%) than with liposomal amphotericin B (25%) (P = 0.002). Nephrotoxicity occurred in 37% of patients treated with amphotericin B and 9% of patients treated with liposomal amphotericin B (P = 0.003).Conclusion: Liposomal amphotericin B seems to be a less toxic alternative to amphotericin B and is associated with improved survival.
ACCESSION #
6981144

 

Related Articles

  • Disseminated Histoplasmosis: Results of Long--Term Follow--up. Sarosi, George A.; Voth, Douglas W.; Dahl, Bernhoff A.; Doto, Irene L.; Tosh, Fred E. // Annals of Internal Medicine;Oct71, Vol. 75 Issue 4, p511 

    Provides information on a study on cases of disseminated histoplasmosis in the U.S. from 1947 to 1969. Results of amphotericin B therapy; Complications of the condition; Mortality of histoplasmosis patients.

  • Long-term amphotericin B therapy for disseminated histoplasmosis in patients with the acquired immunodeficiency syndrome (AIDS). McKinsey, David S.; Gupta, Mala R.; Riddler, Sharon A.; Driks, Michael R.; Smith, David L.; Kurtin, Paul J.; McKinsey, D S; Gupta, M R; Riddler, S A; Driks, M R; Smith, D L; Kurtin, P J // Annals of Internal Medicine;10/15/89, Vol. 111 Issue 8, p655 

    Study Objective: To assess the efficacy and toxicity of long-term maintenance amphotericin B therapy in preventing relapses after treatment in patients with the acquired immunodeficiency syndrome (AIDS) and disseminated histoplasmosis.Design: Open, nonrandomized pilot...

  • LETTER TO THE EDITOR. Parvin, Rukhsana // Journal of Bangladesh College of Physicians & Surgeons;Jan2012, Vol. 30 Issue 1, p58 

    A letter to the editor is presented in response to the article "Chronic Disseminated Histoplasmosis in an Immunocompetent Man Presented as Bilateral Adrenal Masses with Partial Adrenocortical Insufficiency- A Rare Condition," by ABM Sarwar-e-Alam and colleagues in the October 2011 issue.

  • Untitled. Sarwar-e-Alam, A. B. M. // Journal of Bangladesh College of Physicians & Surgeons;Jan2012, Vol. 30 Issue 1, p58 

    A response from the author of the article "Chronic Disseminated Histoplasmosis in an Immunocompetent Man Presented as Bilateral Adrenal Masses with Partial Adrenocortical Insufficiency- A Rare Condition" in the October 2011 issue is presented.

  • Topics in Infectious Diseases. Ellickalputhenpura, Bena E.; Torres, Harrys A. // JAAPA: Journal of the American Academy of Physician Assistants (;Dec2012, Vol. 25 Issue 12, p18 

    The article describes the pathophysiology and management of histoplasmosis, an infectious disease caused by inhalation of microconidia of Histoplasma capsulatum. It reports that the symptoms of it include asymptomatic, pulmonary, disseminated histoplasmosis. It highlights that bronchoalveolar...

  • Disseminated Histoplasmosis and Secondary Hemophagocytic Syndrome in a Non-HIV Patient. Kashif, Muhammad; Tariq, Hassan; Ijaz, Mohsin; Gomez-Marquez, Jose // Case Reports in Critical Care;8/10/2015, Vol. 2015, p1 

    Histoplasma duboisii, a variant of Histoplasma capsulatum that causes “African histoplasmosis,” can be resistant to itraconazole, requiring intravenous amphotericin B treatment. Rarely, these patients do not respond to intravenous antifungal therapy, and in such cases, patients may...

  • Drug News. Scholz, Mary // RN;Dec89, Vol. 52 Issue 12, p109 

    Presents news and information related to drugs as of December 1989. Effectiveness of the antifungal drug amphotericin B in the treatment of AIDS-related histoplasmosis; Use of amoxacillin in the treatment of impetigo; Cause of impetigo; Mechanism of action of the antipsychotic drug clozapine in...

  • Prevention of Relapse of Histoplasmosis with Intraconazole in Patients with Acquired Immunodeficiency Syndrome. Wheat, Joseph; Hafner, Richard; Wulfsohn, Michael; Spencer, Patrician; Squires, Kathleen; Powderly, William; Wong, Brian; Rinaldi, Michael; Saag, Michael; Hamill, Richard; Murphy, Robert; Connolly-Stringfield, Patricia; Briggs, Necia; Owens, Susan // Annals of Internal Medicine;4/15/93, Vol. 118 Issue 8, p610 

    Assesses the efficacy and safety of itraconazole in preventing relapse of histoplasmosis after induction therapy with amphotericin B in patients with acquired immunodeficiency syndrome and disseminated histoplasmosis. Research design; Results; Conclusion.

  • Histoplasmosis laríngea: reporte de primer caso en Colombia. Moriones Robayo, Carlos Alberto; Guerra Ortiz, Claudia Patricia // Colombia Medica;Oct-Dec2014, Vol. 45 Issue 4, p186 

    Laryngeal histoplasmosis usually occurs in immunocompromised patients through the dissemination of the fungus from the lungs to other organs. Histoplasmosis isolated laryngeal (primary) is rare. If a patient presents with a history of renal transplant immunosuppression, primary histoplasmosis...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics